High-throughput screening of perovskite-based electrochemical sensor for determination of piroxicam via electrocatalytic oxidation in pharmaceutical and biomedical analysis

Piroxicam is a drug from the oxicam family and is an anti-inflammatory one which is used to relieve pain in humans. In this research work, the electrochemical modifier agents are perovskite nanosheets, graphene oxide (GO) and their effective nanocomposite. The morphology of La(Fe0.7Mn0.3)(0.9)Pd0.1O3, GO, and La (Fe0.7Mn0.3)(0.9)Pd0.1O3/GO nanocomposite were examined by SEM, EDX, FTIR, XPS and XRD analysis. The results obtained from the surface analysis of nanocomposite materials represent the compatibility of the intended perovskite structure with the cubic one. Also, GO has affected the main structure of the composite material. According to the results for the perovskite, the porous structure is shown and GO is well placed in the porous structure of the perovskite. Furthermore, the presence of elements in the perovskite structure was confirmed by EDX. Cyclic voltammetry (CV) and Differential pulse voltammetry (DPV) techniques were used to investigate the electrochemical behavior of piroxicam and quantification, respectively. The above-mentioned electrode has been utilized to determine the piroxicam. In which, LOD (limit of detection) and the linear range were acquired 0.89 mu M and 6-103 mu M respectively for piroxicam oxidation process. Eventually, the designed sensing assay was used for the detection and quantification of piroxicam in capsule and human plasma samples. The obtained results from the designed sensor specify acceptable analytical characteristics consisting of low LOD, widespread linear range, and adequate proficiency for the highly sensitive determination of piroxicam. Additionally, La (Fe0.7Mn0.3)(0.9)Pd0.1O3/GO GCE showed acceptable stability, repeatability, and reproducibility. To investigate the accuracy of the mentioned assay, the recovery index of 96.41% (RSD <5%) indicates the high performance in real samples.